
S&P/ASX 200 Index (ASX: XJO) shares are 0.14% higher at 8,828.7 points on Tuesday.
The fastest rising ASX 200 share today is WiseTech Global Ltd (ASX: WTC), which has recovered 4% after yesterday's smashing.
ASX 200 healthcare shares Telix Pharmaceuticals Ltd (ASX: TLX) and Mesoblast Ltd (ASX: MSB) are also among the top risers today.
Both stocks are up by more than 3.5%.
Meanwhile, let's check out 3 ASX 200 shares with new ratings from the experts (courtesy The Bull).
The Charter Hall share price is $22.73, down 0.5% today and down 7% in the calendar year to date (YTD).
Toby Grimm from Baker Young has a buy rating on this real estate investment trust (REIT).
The analyst said:
Australia's leading diversified property group has benefited from a strong funds management performance driving multiple earnings upgrades in the past financial year.
With the strong operational trend continuing amid a potential respite in interest rates, the stock offers compelling exposure in a lagging sector that may be a beneficiary of a swing against banks.
The shares have been enjoying favourable momentum since May 20, increasing from $18.80 to trade at $23.15 on June 18.
The Cochlear share price is $112.38, down 0.5% today and down 57% YTD.
Christopher Watt from Bell Potter has a hold rating on this ASX 200 healthcare share.
Watt explained:
The long term opportunity for this hearing implants maker remains compelling, supported by a large addressable market, strong brand position and an attractive product pipeline.
However, near term trading conditions have softened in response to weaker referral activity in the US, hospital capacity constraints in Europe and reimbursement changes in China.
Until there's clearer evidence that volumes are stabilising, a more balanced stance is appropriate.
The long term growth story and product pipeline remain intact.
The S&P/ASX 200 Health Care Index (ASX: XHJ) fell to a 9-year low on 3 June due to many industry headwinds over the past year.
Since then, ASX 200 healthcare shares have been on a comeback, rising 11.5% compared to a 0.4% bump for the broader ASX 200.
The Northern Resources share price is $20.93, down 1.3% on Tuesday and down 14% YTD.
Grimm has a sell rating on this ASX 200 gold mining share.
He explained:
The emergence of prominent US based activist investor Elliott Investment Management has prompted optimism surrounding the gold miner.
However, in our view, it doesn't alter the underperformance of NST's asset base involving production volumes, costs and capital expenditure requirements.
A new management team will likely rebase expectations. But we would seek alternative gold exposure for those still playing the theme.
The shares have fallen from $31.73 on March 2 to trade at $21.44 on June 18.
Elliot Investment recently disclosed it has a 3% to 4% stake in Northern Star shares.
It also suggested ways that Northern Star management could improve returns for shareholders.
You can read Northern Star's response here.
The post Buy, hold, sell: Charter Hall, Northern Star, Cochlear shares appeared first on The Motley Fool Australia.
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Telix Pharmaceuticals. The Motley Fool Australia has recommended Cochlear and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026